GS 0321
Alternative Names: COM-503; GS-0321Latest Information Update: 15 Jan 2025
At a glance
- Originator Compugen
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Interleukin-18 binding protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 07 Jan 2025 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Recurrent, Combination therapy) in USA (IV) (NCT06759649)
- 06 Jan 2025 Phase-I clinical trials in Solid tumours (Monotherapy, Late-stage disease, Metastatic disease, Recurrent) in USA (IV) (NCT06759649)
- 19 Nov 2024 Compugen plans to initiate phase I clinical trial for COM 503 in Solid tumors (Late-stage disease) in the fourth quarter of 2024